Navigation Links
Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
Date:3/12/2010

As of December 31, 2009, we had $50.9 million in cash, cash equivalents, and short-term investments, and $1.4 million in receivables, compared to $57.7 million in cash, cash equivalents, and short-term investments, and $0.4 million in receivables as of December 31, 2008. The net decrease in cash, cash equivalents, short-term investments and receivables for 2009 was primarily due to the use of cash to fund our clinical-stage programs, personnel costs and for other general corporate purposes, partially offset by the receipt of a $35.0 million non-refundable, upfront license fee and the reimbursement of third-party development costs associated with our MEK inhibitor program under our license agreement with Bayer.

We anticipate that our existing cash, cash equivalents and short-term investments will be sufficient to fund our operating activities through the first quarter of 2011. This projection does not include forecasted expenses for Phase 3 development of RDEA594, the receipt of any milestone payments under our license agreement with Bayer, proceeds from future partnering activities or financings, or payments to Valeant under our asset purchase agreement.

Revenues totaled $8.3 million and $22.9 million for the thr
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Drug delivery technologies that ... essential part of the entire drug development process. ... in new vaccine delivery technologies in a bid ... skin delivery procedures. New analysis from ... though the needle-free delivery sector currently makes up ...
(Date:9/2/2014)... COSTA MESA, Calif. , Sept. 2, 2014 ... organization was just recognized as one of the ... Over the past few years, the company has ... phase clinical research, late phase global clinical development, ... the past 2 years, WCCT Global has successfully ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... market research report is available in its catalogue: ... 2014 - 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... (ADCs) are a new class of therapeutic agents, ... pharmaceutical companies. Generally addressed as the marriage of ...
Breaking Medicine Technology:Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18
... USCAP MeetingSOUTH SAN FRANCISCO, Calif., March 13 Rigel ... the enrollment of the first patient in a Phase ... patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). ... the efficacy of R788, an orally bio-available Syk kinase ...
... Phase II Study Published in The Lancet of Fast-Tracked ... Minor Bleeding and was Well Tolerated When Given With ... a Schering-Plough Corporation (NYSE: SGP ) Phase ... receptor antagonist (TRA), were published today in The ...
Cached Medicine Technology:Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 2Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present its ... Get Up! Get Moving!®. This event promotes Hispanic family physical ... people of all ages and all sizes. The event, which ... at Kiest Park Recreation Center, 3080 S. Hampton Road, in ... 2007, we have partnered with National Alliance for Hispanic Health ...
(Date:9/2/2014)... September 02, 2014 West Hollywood ... complimentary consultations for Invisalign. This special offer includes a ... smiles to determine their candidacy for the procedure and ... Qualified patients may also be eligible for the Summer ... remainder of the month of August, patients who choose ...
(Date:9/2/2014)... 1, 2014 (HealthDay News) -- The quality of Americans, ... dietary disparity between the rich and poor is growing, ... most direct evidence to date that the extensive efforts ... quality are having some payoff, but it also indicates ... Dong Wang, a doctoral student in the department of ...
(Date:9/2/2014)... it comes to excess pounds and blood pressure, all fat ... The research found that belly fat -- the proverbial "spare ... more than overall body fat. It,s well known that ... wasn,t clear how the location of fat in the body ... Southwestern Medical Center in Dallas. Reporting Sept. 1 in ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 North ... America Resectoscopes Market Outlook to 2020? provides key ... The report provides value, in millions of US ... US dollars) within market segments –, ... (Disposable and Reusable) Electrodes and Bipolar (Disposable and ...
Breaking Medicine News(10 mins):Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Quality of U.S. Diet Improves, Slightly 2Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4
... Legislation Introduced to Fund Lung Cancer ResearchBOSTON, Jan. ... Senator Susan Fargo (D-3rd Middlesex), the Senate Chair ... once again introducing comprehensive legislation that creates a ... http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO )"Now is the time for positive ...
... (Nasdaq: ROCM ) today announced that Covidien ... litigation which Rochester Medical,filed on March 16, 2004 against ... L.P.; Novation, LLC; VHA Inc.; and Premier Purchasing,Partners L.P. ... of the settlement, Rochester Medical, represented by The,Lanier Law ...
... festival in Park,City, Utah, usually known for power lunches, will ... full-service fitness center, called,the "G Gym." Actors Eliza Dushku ... of the many celebrities to snatch up appointments with top,Hollywood ... or $1,000 for,charity, up to $20,000. , ...
... YORK, Jan. 15 On Tuesday, February 3, 2009, ... The Fifth Annual Beyond Beauty Gala to benefit The ... genetic research and awareness for Obsessive-Compulsive Disorder (OCD). ... evening,s event will be held at The Union League ...
... Package and House Vote to Expand Child Health InsuranceTUCSON, Ariz., ... Corporation (Nasdaq: PRSC ) today provided an update ... package being sought by President-elect Barack Obama as well as ... insurance. The economic stimulus package under discussion includes aid ...
... Roxane Laboratories, Inc.,announced today the approval of their ... 500mg, 750mg, 1000mg, and Oral Solution,100mg/mL. The product ... nationwide. , Roxane Laboratories, ... UCB, Inc.,s KEPPRA(R) (levetiracetam). Annual sales of KEPPRA(R) ...
Cached Medicine News:Health News:Lung Cancer Alliance Hails Massachusetts State Senator for Taking Lead on Lung Cancer 2Health News:Celebrities Stay Fit at First Ever Full-Service Luxury Gym at Film Festival in Park City, Utah 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 3Health News:Providence Service Corporation Provides Update on Potential Medicaid 2Health News:Providence Service Corporation Provides Update on Potential Medicaid 3Health News:Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution 2
... The Finnpipette BioControl multichannel ... as the single channel model. ... all seven multichannel and five ... Both pipettes have a recharge ...
... solution and best value in high performance ... and ultra lightweight design reduce hand fatigue ... long, lever tip ejector , Color coding ... tips or for greater performance use Hamilton ...
... Pipette is ideal for all liquid handling ... ergonomically-placed operating buttons, and various dispensing techniques ... diluting make this a lab favorite. It ... manual pipette without any adverse effects on ...
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
Medicine Products: